Asset Details
Do you wish to reserve the book?
The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
Do you wish to request the book?
The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
2023
Overview
Palis and MacDonald respond to letters discussing the use of prescribed psychostimulants to treat stimulant use disorder. They address comments made by various colleagues regarding the evidence supporting the use of prescription psychostimulants. They acknowledge that while the evidence is not as strong as that for medications used to treat other substance use disorders, such as opioid use disorder, this should not be a barrier to implementing prescription psychostimulants. They argue that the level of evidence available for opioid agonist treatment (OAT) should not be the benchmark for action on implementing prescription psychostimulants. They agree with the need for broader psychiatric supports, medical care, housing, and psychosocial treatments for people with stimulant use disorder. However, they argue that direct patient care is within the scope of practice for prescribers and can have immediate impacts on patients' lives. They call for the development of evidence and clinical protocols to guide the use of prescription psychostimulants and advance care for this population.
Publisher
Elsevier Inc,CMA Impact Inc,CMA Impact, Inc
Subject
